23,495 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Bought by Graham Capital Management L.P.

Graham Capital Management L.P. bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 23,495 shares of the medical equipment provider’s stock, valued at approximately $1,299,000.

A number of other hedge funds have also modified their holdings of LNTH. Advisor Group Holdings Inc. grew its holdings in shares of Lantheus by 6.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 17,576 shares of the medical equipment provider’s stock worth $507,000 after acquiring an additional 1,031 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Lantheus by 11.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 30,881 shares of the medical equipment provider’s stock worth $892,000 after acquiring an additional 3,076 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Lantheus by 17.0% in the 4th quarter. Principal Financial Group Inc. now owns 555,077 shares of the medical equipment provider’s stock worth $16,036,000 after acquiring an additional 80,665 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Lantheus by 21.8% in the 4th quarter. Teacher Retirement System of Texas now owns 13,162 shares of the medical equipment provider’s stock worth $380,000 after acquiring an additional 2,359 shares during the last quarter. Finally, Citigroup Inc. grew its holdings in shares of Lantheus by 18.9% in the 4th quarter. Citigroup Inc. now owns 52,244 shares of the medical equipment provider’s stock worth $1,509,000 after acquiring an additional 8,290 shares during the last quarter. 98.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 386 shares of the business’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $69.12, for a total value of $26,680.32. Following the transaction, the chief accounting officer now owns 64,255 shares in the company, valued at $4,441,305.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Lantheus news, COO Paul Blanchfield sold 1,500 shares of the business’s stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $83.39, for a total value of $125,085.00. Following the completion of the sale, the chief operating officer now owns 76,143 shares of the company’s stock, valued at $6,349,564.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Andrea Sabens sold 386 shares of the business’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $69.12, for a total value of $26,680.32. Following the completion of the sale, the chief accounting officer now directly owns 64,255 shares of the company’s stock, valued at approximately $4,441,305.60. The disclosure for this sale can be found here. Insiders have sold 8,751 shares of company stock worth $700,218 over the last 90 days. 1.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LNTH has been the topic of a number of research analyst reports. B. Riley reiterated a “buy” rating on shares of Lantheus in a report on Thursday, August 25th. SVB Leerink lifted their price target on Lantheus from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Friday, August 5th.

Lantheus Stock Performance

Shares of LNTH stock opened at $85.05 on Monday. Lantheus Holdings, Inc. has a 1-year low of $22.20 and a 1-year high of $86.85. The company has a current ratio of 1.85, a quick ratio of 1.69 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $5.85 billion, a price-to-earnings ratio of 197.79 and a beta of 0.77. The stock’s fifty day simple moving average is $75.96 and its 200-day simple moving average is $65.51.

Lantheus (NASDAQ:LNTHGet Rating) last issued its earnings results on Thursday, August 4th. The medical equipment provider reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.17. Lantheus had a return on equity of 28.88% and a net margin of 4.88%. The firm had revenue of $223.80 million for the quarter, compared to the consensus estimate of $204.51 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The business’s quarterly revenue was up 121.4% compared to the same quarter last year. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 3.29 earnings per share for the current fiscal year.

Lantheus Profile

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Further Reading

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.